{"title":"[Clinical Characteristics and Prognosis Analysis of Angioimmunoblastic T-Cell Lymphoma].","authors":"Hong-Bo Wang, Xiu-Juan Wang, Xin-Hong Guo","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 42 AITL patients who were diagnosed and monitored in the Hematologic Disease Center of the First Affiliated Hospital of Xinjiang Medical University from 2011 to 2021. Kaplan-Meier method was used to calculate overall survival (OS) rate and progression-free survival (PFS) rate, while log-rank method was utilized for comparison.</p><p><strong>Results: </strong>The majority of 42 patients were elderly, with a median age at diagnosis of 66(22-80) years old, and 25 cases were males. There were 38 patients in Ann Arbor stage III-IV, 23 patients with B symptoms, and 34 patients with intermediate-high to high risk of International Prognostic Index (IPI) score. The most common clinical manifestation was painless lymph node swelling (31 cases), which could be accompanied by multiple serous effusion (24 cases), fever (17 cases), rash (11 cases), and anemia (15 cases). There were 18 patients with positive Epstein-Barr virus (EBV), 28 patients with Ki-67 ≥40%, and 6 patients accompanied by EBV viremia. The median survival time of the 42 patients was 12(1-121) months, 3-year OS rate was 37.6%, and 3-year PFS rate was 26.1%. Univariate analysis indicated that patients with elevated interleukin (IL)-6 and multiple serous effusion exhibited lower survival rate.</p><p><strong>Conclusion: </strong>AITL is characterized by diverse clinical manifestations, high aggressiveness and poor prognosis. Conventional chemotherapy is not effective. Elevated IL-6 and multiple serous effusion are poor prognostic factors for AITL patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"108-113"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的：研究血管免疫母细胞T细胞淋巴瘤（AITL）患者的临床特征和预后因素：研究血管免疫母细胞T细胞淋巴瘤（AITL）患者的临床特征和预后因素：方法：对2011年至2021年在新疆医科大学第一附属医院血液病中心确诊和监测的42例AITL患者的临床资料进行回顾性分析。采用Kaplan-Meier法计算总生存率（OS）和无进展生存率（PFS），并采用对数秩方法进行比较：42例患者中大多数为老年人，确诊时的中位年龄为66（22-80）岁，25例为男性。38 名患者处于 Ann Arbor III-IV 期，23 名患者有 B 型症状，34 名患者的国际预后指数（IPI）评分为中高危。最常见的临床表现是无痛性淋巴结肿大（31 例），可伴有多发性浆液性渗出（24 例）、发热（17 例）、皮疹（11 例）和贫血（15 例）。18例患者Epstein-Barr病毒（EBV）阳性，28例患者Ki-67≥40%，6例患者伴有EBV病毒血症。42名患者的中位生存时间为12（1-121）个月，3年OS率为37.6%，3年PFS率为26.1%。单变量分析表明，白细胞介素（IL）-6升高和多浆液性渗出的患者生存率较低：结论：AITL具有临床表现多样、侵袭性强、预后差等特点。结论：AITL 临床表现多样，侵袭性强，预后差，常规化疗效果不佳。IL-6升高和多浆液性渗出是AITL患者预后不良的因素。
[Clinical Characteristics and Prognosis Analysis of Angioimmunoblastic T-Cell Lymphoma].
Objective: To investigate the clinical characteristics and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).
Methods: A retrospective analysis was conducted on the clinical data of 42 AITL patients who were diagnosed and monitored in the Hematologic Disease Center of the First Affiliated Hospital of Xinjiang Medical University from 2011 to 2021. Kaplan-Meier method was used to calculate overall survival (OS) rate and progression-free survival (PFS) rate, while log-rank method was utilized for comparison.
Results: The majority of 42 patients were elderly, with a median age at diagnosis of 66(22-80) years old, and 25 cases were males. There were 38 patients in Ann Arbor stage III-IV, 23 patients with B symptoms, and 34 patients with intermediate-high to high risk of International Prognostic Index (IPI) score. The most common clinical manifestation was painless lymph node swelling (31 cases), which could be accompanied by multiple serous effusion (24 cases), fever (17 cases), rash (11 cases), and anemia (15 cases). There were 18 patients with positive Epstein-Barr virus (EBV), 28 patients with Ki-67 ≥40%, and 6 patients accompanied by EBV viremia. The median survival time of the 42 patients was 12(1-121) months, 3-year OS rate was 37.6%, and 3-year PFS rate was 26.1%. Univariate analysis indicated that patients with elevated interleukin (IL)-6 and multiple serous effusion exhibited lower survival rate.
Conclusion: AITL is characterized by diverse clinical manifestations, high aggressiveness and poor prognosis. Conventional chemotherapy is not effective. Elevated IL-6 and multiple serous effusion are poor prognostic factors for AITL patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
